A New Drug for Early-Stage Breast Cancer Treatment: Neratinib

The greatest advance in cancer medicine has undoubtedly been in breast cancer treatment. Indeed, the first hormonal treatment (tamoxifen) and the first targeted smart drug treatment (trastuzumab) resulted from major efforts to understand and treat breast cancer. A study newly published in NEJM, one of the leading scientific journals, concerns neratinib, a drug thought likely to have an important place in future breast cancer treatment.
Neratinib is a tyrosine kinase inhibitor. It irreversibly blocks the tyrosine kinase activity of the intracellular portion of Human Epidermal Growth Factor Receptors (EGFR, HER2, HER4), thereby suppressing growth and proliferation signals within cancer cells.
The I-SPY 2 study discussed here is a multicenter, randomized phase 2 trial. All HER2-positive, hormone receptor-negative patients enrolled received the standard chemotherapy regimen of 4 cycles of cyclophosphamide–Adriamycin and 12 weeks of paclitaxel. The investigational drug neratinib was added to paclitaxel treatment and compared with the standard arm.
The primary endpoint of the study was pathological complete response, while secondary endpoints were event-free survival and overall survival. In this phase II study, patients were first randomized into 10 prospective subgroups using HER2 status, hormone receptor status, and the 70-gene MammaPrint analysis. In the HER 2-positive, hormone receptor-negative group, the predicted pathological complete response (Bayesian predictive probability) was calculated from the rate of tumor shrinkage on MRI during treatment. The group with the successful biomarker signature showing a high Bayesian predictive probability proceeded to a phase III trial.
According to the study results, the HER2-positive, hormone receptor-negative patient group achieved a notably good pathological complete response rate of 56% with the neratinib combination in phase III, compared with 33% in the control arm. The most frequent adverse effects reported in the neratinib arm were neutropenia (low white blood cell count), diarrhea, and elevated liver enzymes.
In conclusion, HER2-positive, hormone receptor-negative adding neratinib to standard chemotherapy in breast cancer was shown to significantly improve treatment success. Neratinib is hoped to become part of standard treatment for this patient group in the coming period.
Sources
Adaptive Randomization of Neratinib in Early Breast Cancer.
N Engl J Med 2016; 375:11-22July 7, 2016DOI: 10.1056/NEJMoa1513750
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.